TRPV4 and diabetes mellitus: Given that potent and selective TRPV4 antagonists are available39,47, we evaluated the outcome of TRPV4 antagonist intravitreal injection after enhanced BRB breakdown due to experimental diabetes induced by streptozotocin and found that TRPV4 antagonism mitigated BRB breakdown to similar levels than vasoinhibins.